Clinical Trials Logo

Clinical Trial Summary

This is a phase I clinical study to evaluate the safety and tolerability of C-4-29 in patients with relapsed or refractory multiple myeloma, and to obtain the maximum tolerated dose of C-4-29 and phase II Recommended dose.


Clinical Trial Description

This is a multi-center, single-arm, open-label study. The study plans to set up 3 dose groups, adopting a dose-escalating 3+3 design, and plan to recruit about 9-18 subjects with relapsed or refractory multiple myeloma.C-4-29 cells will be infused to the subject by intravenous infusion. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04861480
Study type Interventional
Source Chongqing Precision Biotech Co., Ltd
Contact
Status Enrolling by invitation
Phase Phase 1
Start date June 16, 2021
Completion date July 18, 2024

See also
  Status Clinical Trial Phase
Active, not recruiting NCT01435720 - Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL) Phase 1/Phase 2
Recruiting NCT04094961 - Ixazomib + Pomalidomide + Dexamethasone In MM Phase 1/Phase 2
Recruiting NCT06068400 - Clinical Study to Evaluate the Safety and Efficacy of CAR-T in the Treatment of Multiple Myeloma N/A
Recruiting NCT03601624 - Pomalidomide/Cyclophosphamide/Dexamethasone in Relapse Refractory Myeloma: Safety Profile in Mexicans Phase 2
Recruiting NCT05020444 - TriPRIL CAR T Cells in Multiple Myeloma Phase 1
Not yet recruiting NCT03706547 - Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM Phase 1
Active, not recruiting NCT02970747 - Non-interventional Study of Kyprolis® in Combination With Revlimid® and Dexamethasone or Dexamethasone Alone or in Combination With Darzalex® and Dexamethasone in Multiple Myeloma Patients
Completed NCT01965353 - A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma Phase 1
Not yet recruiting NCT05581875 - A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory Phase 1/Phase 2
Terminated NCT03687125 - Tinostamustine Conditioning and Autologous Stem Cell Phase 1/Phase 2
Recruiting NCT06282978 - Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes Phase 2
Recruiting NCT06158412 - All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma Phase 2
Active, not recruiting NCT03030261 - Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma Phase 2
Recruiting NCT04925193 - Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma Phase 2
Recruiting NCT05121103 - A Study of the Safety, Tolerability and Effectiveness of EZM0414 Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma Phase 1
Recruiting NCT04603872 - CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies Early Phase 1
Recruiting NCT04657861 - APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma Early Phase 1
Terminated NCT05191472 - Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies Phase 2
Completed NCT03136653 - A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple Myeloma Phase 1/Phase 2
Recruiting NCT04162353 - BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma Phase 1